1-1 of 1
tumor lysis syndrome
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL

Clinical Trials & Observations
Arnon P. Kater, Sabina Kersting, Yvette van Norden, Julie Dubois, Johan A. Dobber, Clemens H. Mellink, Ludo M. Evers, Fransien Croon-de Boer, John Schreurs, Ellen van der Spek, Hein Visser, Cecile Idink, Shulamiet Wittebol, Mels Hoogendoorn, Sanne H. Tonino, Mehrdad Mobasher, Mark-David Levin
Journal: Blood Advances
Blood Adv (2018) 2 (24): 3566–3571.
https://doi.org/10.1182/bloodadvances.2018019422
Published: 2018
Includes: Supplemental data